152 related articles for article (PubMed ID: 22421409)
1. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes.
Germing U; Strupp C; Giagounidis A; Haas R; Gattermann N; Starke C; Aul C
Leuk Res; 2012 Jun; 36(6):727-34. PubMed ID: 22421409
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS).
Cantù Rajnoldi A; Fenu S; Kerndrup G; van Wering ER; Niemeyer CM; Baumann I;
Ann Hematol; 2005 Jul; 84(7):429-33. PubMed ID: 15838669
[TBL] [Abstract][Full Text] [Related]
3. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
[TBL] [Abstract][Full Text] [Related]
4. AIDS-related bone marrow lesions--myelodysplastic features or predominant inflammatory-reactive changes (HIV-myelopathy)? A comparative morphometric study by immunohistochemistry with special emphasis on apoptosis and PCNA-labeling.
Thiele J; Zirbes TK; Bertsch HP; Titius BR; Lorenzen J; Fischer R
Anal Cell Pathol; 1996 Aug; 11(3):141-57. PubMed ID: 8888951
[TBL] [Abstract][Full Text] [Related]
5. Some aspects of morphological and dysplastic changes of the bone marrow in malignant lymphoma.
Jakovleva K; Everaus H
Acta Haematol; 1998 Dec; 100(3):142-6. PubMed ID: 9858791
[TBL] [Abstract][Full Text] [Related]
6. [Classification and clinical findings of myelodysplastic syndromes].
Tsuruda K; Hasegawa H; Fuchigami M; Uno N; Morinaga Y; Miyazaki Y; Yanagihara K
Rinsho Byori; 2014 Apr; 62(4):359-68. PubMed ID: 25022065
[TBL] [Abstract][Full Text] [Related]
7. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
8. [Myelodysplastic syndromes. The epidemiological and etiological aspects].
Aul C; Gattermann N; Germing U; Runde V; Heyll A
Dtsch Med Wochenschr; 1992 Aug; 117(33):1223-31. PubMed ID: 1499520
[TBL] [Abstract][Full Text] [Related]
9. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and therapy strategy in myelodysplastic syndromes].
Gattermann N; Aul C
Praxis (Bern 1994); 1996 Jan; 85(3):39-44. PubMed ID: 8578048
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes.
Germing U; Aul C; Niemeyer CM; Haas R; Bennett JM
Ann Hematol; 2008 Sep; 87(9):691-9. PubMed ID: 18575866
[TBL] [Abstract][Full Text] [Related]
12. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
13. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
14. [A feature of hematological findings in myelodysplastic syndromes].
Bando S; Niiya T; Murase M; Makino H
Rinsho Byori; 1998 Aug; 46(8):790-5. PubMed ID: 9760831
[TBL] [Abstract][Full Text] [Related]
15. [Myelodysplastic syndromes].
Solary E; Fontenay M
Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
[TBL] [Abstract][Full Text] [Related]
16. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
Tauro S; Hepburn MD; Bowen DT; Pippard MJ
Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
[TBL] [Abstract][Full Text] [Related]
17. Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes.
Goasguen JE; Bennett JM; Bain BJ; Brunning R; Vallespi MT; Tomonaga M; Zini G; Renault A;
Leuk Res; 2014 Apr; 38(4):447-53. PubMed ID: 24439566
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic value of dysplasia characteristics in typing of myelodysplastic syndrome].
Li J; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):657-61. PubMed ID: 23815917
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes with monocytic component: hematologic and cytogenetic characterization.
Rigolin GM; Cuneo A; Roberti MG; Bardi A; Castoldi G
Haematologica; 1997; 82(1):25-30. PubMed ID: 9107078
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes.
Horny HP; Sotlar K; Valent P
Leuk Res; 2007 Dec; 31(12):1609-16. PubMed ID: 17604834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
